Given Douglas B's Form 4 filing
Arrowhead Pharmaceuticals, Inc. (ARWR) · filed Dec 29, 2021
- Accession no.
- 0001209191-21-071563
- Filed
- Dec 29, 2021
- Trade date
- Dec 28, 2021
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions. Open-market purchases total $43.5K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Given Douglas BCIK 0001156207 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 28, 2021 | Common Stock | GGiftDisposed | −655 | $0.00 | $0 | 109,213 | Direct | |
| Dec 28, 2021 | Common Stock | PPurchaseAcquired | +655 | $66.37 | +$43,472.35 | 109,868 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.